octreotide acetate / Generic mfg. - LARVOL DELTA

177Lu-DOTATATE versus high-dose long-acting octreotide for somatostatin receptor-positive advanced GEP-NETs: A multicenter, randomised, open-label, positive-controlled phase III study (ESMO Asia 2025) - P3 | "177Lu-DOTATATE had an acceptable safety profile in GEP-NETs pts with PFS improvement versus high-dose long-acting octreotide."

Clinical • Late-breaking abstract • Metastases • P3 data • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • SSTR

Axitinib and Long-Acting Octreotide in Advanced Extrapancreatic Neuroendocrine Tumors: A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial (AXINET, GETNE 1107). (PubMed, J Clin Oncol) - "Axitinib significantly increased PFS per BICR assessment and ORR both per investigator and BICR assessment compared with placebo, although the primary study end point was not met. Toxicity profile was manageable with no new safety concerns."

Clinical • Journal • P3 data • Cardiovascular • Gastrointestinal Neuroendocrine Tumor • Hypertension • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Hoffa's Fat Pad Impingement (HFPI) (clinicaltrials.gov) - P4 | N=62 | Recruiting | Sponsor: Boston Children's Hospital | Not yet recruiting ➔ Recruiting | Phase classification: PN/A ➔ P4 | Not yet recruiting ➔ Recruiting

Enrollment open • Phase classification

Real-World Observational Study of Somatostatin Analogs and Rescue Medication Usage for Neuroendocrine Tumors in Canada. (PubMed, Neuroendocrinology) - "Switching between long-acting SSAs can reduce the need for breakthrough medications and lower the incidence of AMRD prescriptions, with a more pronounced effect observed when switching from OCT-LAR to LAN-ATG. These findings have potential implications for improving quality of life and reducing treatment costs for NET patients, which should be evaluated in a formal health economic analysis."

Journal • Observational data • Real-world evidence • Carcinoid Syndrome • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

[177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Primary analysis of the phase 3 randomized NETTER-2 study. (ASCO-GI 2024) - P3 | "177Lu-DOTATATE significantly prolonged PFS and demonstrated a clinically meaningful ORR, compared with high-dose octreotide LAR, in pts with newly diagnosed advanced G2 and G3 GEP-NETs. Safety was in line with the established profile of 177Lu-DOTATATE. This is the first randomized study to demonstrate efficacy of RLT as 1L treatment in any malignancy and will change clinical practice."

Clinical • Late-breaking abstract • Metastases • P3 data • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • SSTR

STRATIFYING BIOCHEMICAL RESPONSE TO SOMATOSTATIN ANALOGS TO GUIDE CARCINOID HEART DISEASE RISK ASSESSMENT (ACC 2026) - " Retrospective analysis was conducted on 53 patients with carcinoid syndrome treated with standard-dose SA (lanreotide 120 mg subcutaneously every 4 weeks or octreotide long-acting release 30 mg intramuscularly every 4 weeks). Biochemical stratification of 5-HIAA response identifies patients at persistent risk for CHD despite SA therapy. Partial responders may benefit from early adjunctive serotonin-lowering therapy, such as telotristat. This approach supports individualized risk-based management, with long-term studies needed to confirm survival benefit."

Carcinoid Syndrome • Cardiovascular • Heart Failure

Transarterial embolization plus octreotide LAR in treating rectal neuroendocrine tumor liver metastases :A single -institutional experience (ENETS 2026) - "TAE plus octreotide LAR can significantly prolong the PFS of rectal NETLMs, especially with HTB over 25%. Selec - ted patients with Ki-67 ≤10%, negative 18FDG-PET/CT and clear tumor margin could derive prognostic advantage from the com - bined treatment."

Clinical • Gastrointestinal Neuroendocrine Tumor • Hepatocellular Cancer • Liver Cancer • Neuroendocrine Tumor • Oncology • Solid Tumor

Surufatinib plus octreotide LAR in patients with grade 1/2 GEP -NETs: A single - arm, prospective, open -label phase II study (ENETS 2026) - "Surufatinib combined with octreotide LAR demon - strated promising efficacy and an acceptable safety profile in G1/ G2-grade GEP-NET patients. These findings warrant further in - vestigation in expanded cohorts, with updated outcomes from the ongoing study to be reported subsequently."

Clinical • P2 data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Renal Disease • CSF1R • FGFR1 • FLT1 • SSTR

Somatostatin analogs in advanced typical and atypical pulmonary carcinoids: A multi -center retrospective analysis from Lung NET database (ENETS 2026) - "MATERIALS AND We conducted a retrospective analy - sis of 50 patients with histologically confirmed advanced typical or atypical pulmonary carcinoids treated with SSAs (octreotide LAR or lanreotide autogel) as first-line systemic therapy across four centers. SSA therapy was associated with prolonged disea - se stabilization in most patients with advanced pulmonary car - cinoids. These findings support the continued use of SSAs as a first-line option in this population, while prospective data are nee - ded to better define predictive factors of response."

Metastases • Retrospective data • Carcinoid Syndrome • Endocrine Cancer • Lung Cancer • Neuroendocrine Neoplasm • Solid Tumor

Real -world clinical outcomes of peptide receptor radionucleotide therapy in patients with well -differentiated gastroenteropancreatic neuroendocrine tumors (ENETS 2026) - "BACKGROUND: Peptide receptor radionuclide therapy (PPRT) with 177Lu-dotatate (Lu-177) is a therapeutic option in progres - sive somatostatin receptor (SSTR) positive gastroenteropan - creatic neuroendocrine tumors (GEP-NETs) who were previ - ously treated with somatostatin analogs (SSA). The NETTER-1 trial demonstrated that this therapy was associated with a longer progression-free survival (PFS) among patients with advanced midgut NETs, compared to octreotide LAR 60mg every 4 weeks...Other treatments were transarterial emboliza - tion (TAE) in 37% of patients and/or systemic treatments such as sunitinib, everolimus or chemotherapy in 13% of patients. In our cohort of SSA exposed progressive well-diffe - rentiated GEP-NETs patients, we observed an inferior DFS than expected when compared with previous publication. We plan to expand our data collection to 2 other tertiary centers in the same province to refine our results."

Clinical • Clinical data • Real-world • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR

A real -world study of surufatinib combined with octreotide LAR in the treatment of advanced neuroendocrine tumors (ENETS 2026) - "Surufatinib combined with octreotide LAR exhibits promising efficacy in advanced NETs, particularly in patients with limited prior treatment exposure. Further prospective validation is warranted."

Metastases • Real-world • Neuroendocrine Tumor • Oncology • Solid Tumor • CSF1R • FGFR1 • FLT1

Timing of somatostatin analogue administration and symptom control in neuroendocrine tumors: A real -world analysis integrating clinical and chronobiological parameters (ENETS 2026) - "A retrospective real-world study of 12 patients treated with octreotide LAR or lanreotide autogel (2022–2025) compared CLINICAL SCIENCE - CLINICAL BIOMARKERS49morning (08:00–12:00) and afternoon (13:00–17:00) injections. This real-world observation suggests that the timing and consistency of somatostatin analogue administration may influence symptom stability and biochemical control in NETs. Aligning therapy with circadian rhythms could represent a simple, non-invasive chronotherapeutic strategy deserving validation in larger prospective studies."

Clinical • Real-world • Neuroendocrine Tumor • Oncology • Solid Tumor • CHGA

SWOG-S0518: Octreotide Acetate and Recombinant Interferon Alfa-2b or Bevacizumab in Treating Patients With Metastatic or Locally Advanced, High-Risk Neuroendocrine Tumor (clinicaltrials.gov) - P3 | N=427 | Active, not recruiting | Sponsor: National Cancer Institute (NCI) | Trial completion date: Jan 2026 ➔ Jan 2027

Trial completion date • Endocrine Cancer • Gastric Cancer • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor • Thyroid Gland Carcinoma

Hepatic Dominant ADPKD With a Rare PKD1 Exon 1–8 Duplication (NKF-SCM 2026) - "RESULTS/CASE DISCUSSION Combination therapy with octreotide LAR and tolvaptan resulted in improvement in abdominal discomfort, stabilization of hepatic size, and reduced proteinuria. CONCLUSION This case highlights an atypical presentation of ADPKD associated with a rare structural PKD1 variant and possible oligogenic modulation, underscoring the importance of comprehensive genetic evaluation and individualized management in patients with disproportionate hepatic involvement."

Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Hepatology • Nephrology • Polycystic Kidney Disease • Renal Disease • NOTCH2 • PKD1 • PRKD1

Peptide Receptor Radionuclide Therapy for Recurrent Neuroendocrine Tumor Liver Metastases After Liver transplantation: A Case Series. (PubMed, Transplant Proc) - "PRRT combined with everolimus-based immunosuppression has demonstrated controllable safety and preliminary antitumor activity in patients with relapsed NETLM after LT who have been strictly screened, but myelosuppression requires close monitoring and timely symptomatic treatment."

Journal • Hematological Disorders • Hepatocellular Cancer • Infectious Disease • Liver Cancer • Neuroendocrine Tumor • Oncology • Renal Disease • Solid Tumor • Transplantation • SSTR

Relationship between absorbed dose and SUV derived from SPECT/CT imaging and dose-response in patients with neuroendocrine tumors treated with [¹⁷⁷Lu]Lu-DOTA-TATE. (PubMed, EJNMMI Res) - P3 | "Through the calculation and analysis of the radionuclide therapy dosimetry based on the SPECT/CT images throughout the PRRT treatment of the patients, the absorbed dose and SUV of the patients can provide important dose guidance for radionuclide therapy, which is helpful to improve the treatment efficacy of the patients."

Journal • Endocrine Cancer • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

Efficacy and Safety of Pharmacologic Therapies in Acromegaly: A Systematic Literature Review and Network Meta-Analysis. (PubMed, J Clin Endocrinol Metab) - "This systematic review and NMA consolidate recent high-quality RCT evidence for acromegaly treatments. Paltusotine emerges as a promising alternative to injectable SRLs, with favorable efficacy, safety, and AE-related discontinuation patterns. These findings may inform clinical decision-making and guideline development, if confirmed by clinical experience."

Journal • Retrospective data • Acromegaly • Endocrine Disorders • SSTR

Comparison of Lanreotide and Octreotide LAR Use and Outcomes for Gastrointestinal Neuroendocrine Tumors in British Columbia, Canada. (PubMed, Cancer Control) - "There was numerically less short acting octreotide use in the LAN group (P = 0.087), with none of these patients requiring short acting octreotide, compared to 8.7% of the OCT group.ConclusionLAN was associated with longer time to cancer progression, as well as less use of short acting rescue octreotide in our population-based cohort. However, given the retrospective design and reimbursement-era differences, these findings should be interpreted cautiously and warrant confirmation in prospective or head-to-head studies."

Clinical • Journal • Retrospective data • Gastrointestinal Neuroendocrine Tumor • Neuroendocrine Tumor • Oncology • Solid Tumor

Nonmetastatic Pulmonary Carcinoid Presenting With Carcinoid Syndrome Despite Negative 5-HIAA: A Case Report. (PubMed, Case Rep Endocrinol) - "Surgery markedly improved carcinoid syndrome symptoms, with residual episodes responding to long-acting octreotide 20-30 mg every 4 weeks...The temporal improvement following resection and response to octreotide established the diagnosis when biochemical testing was uninformative. Clinicians should maintain high suspicion for pulmonary carcinoids in patients with unexplained paroxysmal symptoms, even with negative biochemical testing and absent metastatic disease."

Journal • Carcinoid Syndrome • Carcinoid Tumor • Cardiovascular • Endocrine Cancer • Hepatocellular Cancer • Movement Disorders • Oncology • Pulmonary Disease • Solid Tumor

First-line efficacy of [177Lu]Lu-DOTA-TATE in patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors by tumor grade and primary origin: Subgroup analysis of the phase III NETTER-2 study (ESMO-GI 2024) - P3 | "This preplanned subgroup analysis examined efficacy by NET grade (G2, G3) and NET origin (pancreas, small intestine [SI]). Pts were randomized to receive 4 cycles of 177Lu-DOTATATE (4 × 7.4 GBq) + 30 mg octreotide long-acting release (LAR) every 8 weeks (Q8W) during 177Lu-DOTATATE treatment then Q4W (177Lu-DOTATATE arm; n=151), or 60 mg octreotide LAR Q4W (control arm; n=75). 1L 177Lu-DOTATATE efficacy was maintained across NET grades (G2, G3) and locations (pancreas, SI) and it should be considered a standard of care for this pt population."

Clinical • Metastases • P3 data • Endocrine Cancer • Neuroendocrine Tumor • Oncology • Pancreatic Cancer • Solid Tumor

Hemorrhagic jejunal vascular malformations with loop telangiectasia in Turner's syndrome. (PubMed, Clin Res Hepatol Gastroenterol) - "Still, because loop telangiectasias in Turner's syndrome are tiny, superficial vascular lesions, we attempted a similar treatment to that of angiodysplasia (5), with first-line (argon plasma coagulation) and second-line (long-acting release octreotide), resulting in significant biological improvement in our patient. At 6 months of follow-up after octreotide optimization, no recurrence occurred, hemoglobin rate was 14.1 g/dL with ferritinemia at 16 ng/mL."

Journal • Cardiovascular • Endocrine Disorders • Gastroenterology • Hematological Disorders • Psychiatry • Thrombosis • Turners Syndrome • Women's Health

Octreotide long-acting release in the treatment of autosomal dominant polycystic kidney disease: a meta-analysis. (PubMed, Front Endocrinol (Lausanne)) - "These findings provide a certain reference for the clinical treatment of ADPKD; however, additional high-quality studies are still needed for further validation. https://www.crd.york.ac.uk/prospero/, identifier CRD420251242104."

Clinical • Journal • Retrospective data • Review • Autosomal Dominant Polycystic Kidney Disease • Genetic Disorders • Nephrology • Polycystic Kidney Disease • Renal Disease

Lugol's solution for preoperative management of a TSH/GH-secreting pituitary adenoma with suboptimal response to octreotide: a case report. (PubMed, Front Endocrinol (Lausanne)) - "Initial long-acting octreotide treatment was ineffective in controlling hyperthyroidism and was discontinued after 5 months. Despite SSTR2/5 positivity, suboptimal response to octreotide suggests tumor heterogeneity or downstream signaling defects. Preoperative Lugol's solution should be considered when SSAs and methimazole fail."

Journal • Acromegaly • Endocrine Disorders • Oncology • Pain • Pituitary Gland Carcinoma • IGF1 • SSTR2

Individualized treatment strategies for primary hepatic neuroendocrine carcinoma: Two case reports and literature review (A CARE-compliant case report). (PubMed, Medicine (Baltimore)) - "The combination of d-TACE, HAIC, and octreotide may provide a potential downstaging approach for unresectable PHNET, but evidence remains preliminary and hypothesis-generating."

Journal • Review • Endocrine Cancer • Infectious Disease • Neuroendocrine Carcinoma • Oncology • Septic Shock • Solid Tumor

Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. (PubMed, Lancet Oncol) - P3 | "Lu-Dotatate treatment did not significantly improve median overall survival versus high-dose long-acting octreotide. Despite final overall survival not reaching statistical significance, the 11·7 month difference in median overall survival with Lu-Dotatate treatment versus high-dose long-acting octreotide alone might be considered clinically relevant. No new safety signals were reported during long-term follow-up."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Endocrine Cancer • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Neuroendocrine Tumor • Oncology • Solid Tumor • SSTR